Poly(ADP-Ribose) polymerase (PARP) inhibitors: Exploiting a synthetic lethal strategy in the clinic

Timothy A. Yap(Royal Marsden Hospital), Johann S. de Bono(Royal Marsden NHS Foundation Trust)

CA A Cancer Journal for Clinicians

January 1, 2011

10.3322/caac.20095

Cited by 209

Related Papers

DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer

|New England Journal of Medicine|2015|2.2k

Survival with Olaparib in Metastatic Castration-Resistant Prostate Cancer

|New England Journal of Medicine|2020|760

METastasis Reporting and Data System for Prostate Cancer: Practical Guidelines for Acquisition, Interpretation, and Reporting of Whole-body Magnetic Resonance Imaging-based Evaluations of Multiorgan Involvement in Advanced Prostate Cancer

|European Urology|2016|326

Biomarkers Associating with PARP Inhibitor Benefit in Prostate Cancer in the TOPARP-B Trial

|Cancer Discovery|2021|160

Ceralasertib (AZD6738), an Oral ATR Kinase Inhibitor, in Combination with Carboplatin in Patients with Advanced Solid Tumors: A Phase I Study

|Clinical Cancer Research|2021|134